Cite
Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer.
MLA
Vecchiotti, Davide, et al. “Elevated NF-ΚB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer.” Cells (2073-4409), vol. 11, no. 13, July 2022, p. N.PAG. EBSCOhost, https://doi.org/10.3390/cells11132118.
APA
Vecchiotti, D., Verzella, D., Di Vito Nolfi, M., D’Andrea, D., Flati, I., Di Francesco, B., Cornice, J., Alesse, E., Capece, D., & Zazzeroni, F. (2022). Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer. Cells (2073-4409), 11(13), N.PAG. https://doi.org/10.3390/cells11132118
Chicago
Vecchiotti, Davide, Daniela Verzella, Mauro Di Vito Nolfi, Daniel D’Andrea, Irene Flati, Barbara Di Francesco, Jessica Cornice, Edoardo Alesse, Daria Capece, and Francesca Zazzeroni. 2022. “Elevated NF-ΚB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer.” Cells (2073-4409) 11 (13): N.PAG. doi:10.3390/cells11132118.